AZTA

Azenta Inc. provides life sciences sample management and storage solutions enabling pharmaceutical companies, biobanks, academic researchers, and healthcare organizations to preserve and manage biological samples including blood, tissue, DNA, and cell cultures supporting drug discovery, clinical trials, and diagnostic applications. Headquartered in Burlington, Massachusetts, Azenta operates automated sample storage systems maintaining ultra-cold temperatures, robotic sample retrieval systems locating and delivering specimens, and comprehensive sample management software tracking chain of custody and sample metadata. The company's Life Sciences segment serves biopharmaceutical companies conducting drug discovery research requiring storage of millions of compound samples, contract research organizations managing clinical trial specimens, and biobanks preserving genetic materials supporting precision medicine initiatives. Azenta's business model combines capital equipment sales of automated storage systems and laboratory automation products with recurring revenues from service contracts maintaining installed systems, consumables including sample storage tubes and plates, and informatics software subscriptions. The company reported annual revenues of approximately $700-800 million with strong profitability margins reflecting high-value equipment sales and recurring service streams. Recent strategic transformation included divesting the company's semiconductor capital equipment business formerly branded Brooks Automation, allowing focused investment in high-growth life sciences markets where biological sample volumes expand exponentially. Azenta acquired GENEWIZ in 2021 adding genomics services including DNA sequencing, gene synthesis, and molecular biology services complementing core sample storage offerings creating integrated solutions for biopharma customers. Recent initiatives include developing next-generation ultra-cold storage systems improving energy efficiency and capacity density, expanding genomics services capabilities incorporating advanced sequencing technologies, and pursuing international expansion particularly in China and Europe where biopharma research investment accelerates. The company faces competition from automated sample storage vendors including Hamilton Company and LiCONiC, plus in-house solutions where large pharmaceutical companies build proprietary storage infrastructure.